Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

CRISPR Therapeutics AG CRSP

Healthcare  —  Biotechnology
54.23 (1.47) (2.64%) as of 25 Sep
Market cap
$5.4B
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

CRISPR Therapeutics AG (CRSP) Business Profile

Updated before January 2025

Company Overview

CRISPR Therapeutics AG (NASDAQ: CRSP) is a leading biotechnology company specializing in the development of transformative gene-based medicines. Founded in 2013 by Emmanuelle Charpentier, one of the co-discoverers of the CRISPR-Cas9 gene-editing technology, the company is headquartered in Zug, Switzerland, with additional operations in Cambridge, Massachusetts, USA. CRISPR Therapeutics is at the forefront of leveraging CRISPR-Cas9 technology to develop innovative therapies for serious diseases. The company’s leadership team includes CEO Samarth Kulkarni, Ph.D., who has been instrumental in driving the company’s strategic vision and growth, and a board of directors comprising industry veterans and scientific pioneers.

Core Business Segments

CRISPR Therapeutics operates primarily in the field of gene editing and focuses on developing therapies across several key areas:

1. Hemoglobinopathies

The company’s lead programs target hemoglobinopathies, such as sickle cell disease (SCD) and beta-thalassemia. Its flagship product candidate, exagamglogene autotemcel (exa-cel), is being developed in collaboration with Vertex Pharmaceuticals. Exa-cel is designed to edit the patient’s hematopoietic stem cells to produce fetal hemoglobin, potentially curing these debilitating blood disorders.

2. Immuno-Oncology

CRISPR Therapeutics is also advancing a robust pipeline of allogeneic CAR-T cell therapies for cancer treatment. These therapies involve engineering T cells to target and destroy cancer cells. Key candidates in this segment include CTX110, CTX120, and CTX130, which target hematologic malignancies and solid tumors.

3. Regenerative Medicine

The company is exploring the use of CRISPR-Cas9 technology in regenerative medicine, particularly in developing therapies for diabetes. CRISPR Therapeutics is working on gene-edited stem cell-derived therapies to create functional pancreatic cells for insulin production.

4. In Vivo Gene Editing

CRISPR Therapeutics is also developing in vivo gene-editing therapies to address genetic diseases directly within the body. This segment is in its early stages but holds significant potential for treating a wide range of conditions.

Business Model

CRISPR Therapeutics operates on a hybrid business model that combines in-house research and development with strategic partnerships. The company generates revenue primarily through:

  • Collaborations and Licensing Agreements: CRISPR Therapeutics partners with leading pharmaceutical companies, such as Vertex Pharmaceuticals, to co-develop and commercialize therapies. These partnerships provide upfront payments, milestone payments, and royalties on product sales.
  • Product Development: The company invests heavily in advancing its pipeline of gene-editing therapies, aiming to bring transformative treatments to market.
  • Intellectual Property Licensing: CRISPR Therapeutics holds a strong intellectual property portfolio around CRISPR-Cas9 technology, which it licenses to other companies for non-competing applications.

Strategic Direction

CRISPR Therapeutics is focused on expanding its pipeline and advancing its therapies through clinical trials. Key strategic priorities include:

  • Commercialization of Exa-cel: The company is working closely with Vertex Pharmaceuticals to secure regulatory approvals and launch exa-cel for sickle cell disease and beta-thalassemia.
  • Advancing CAR-T Programs: CRISPR Therapeutics aims to expand its allogeneic CAR-T cell therapy portfolio and explore new indications in oncology.
  • Exploring New Therapeutic Areas: The company is investing in early-stage research to apply CRISPR-Cas9 technology to additional diseases, including neurological disorders and autoimmune diseases.
  • Sustainability Goals: CRISPR Therapeutics is committed to ethical and sustainable practices in its research and development activities, ensuring patient safety and long-term viability.

Competitive Landscape

CRISPR Therapeutics operates in a highly competitive biotechnology sector, with key competitors including:

  • Editas Medicine: Another pioneer in CRISPR-based gene editing, focusing on similar therapeutic areas.
  • Intellia Therapeutics: A leader in in vivo gene editing, targeting genetic diseases.
  • Beam Therapeutics: Specializes in base editing, a next-generation gene-editing technology.
  • Bluebird Bio: Focuses on gene therapies for hemoglobinopathies and other genetic disorders.

Despite the competition, CRISPR Therapeutics differentiates itself through its strong partnerships, advanced pipeline, and leadership in CRISPR-Cas9 technology.

Risk Factors

CRISPR Therapeutics faces several risks that could impact its business:

  • Regulatory Challenges: Gene-editing therapies are subject to stringent regulatory scrutiny, which could delay approvals.
  • Market Dependence: The company’s success is heavily reliant on the commercialization of exa-cel and other pipeline products.
  • Supply Chain Disruptions: Manufacturing and supply chain issues could affect the availability of therapies.
  • Competition: The rapidly evolving biotechnology landscape poses a constant threat from competitors.
  • Ethical Concerns: Gene editing raises ethical questions that could influence public perception and regulatory policies.

Recent Developments

  • Exa-cel Clinical Trials: CRISPR Therapeutics and Vertex Pharmaceuticals have reported positive data from late-stage clinical trials of exa-cel, bringing the therapy closer to regulatory approval.
  • CAR-T Advancements: The company has initiated new clinical trials for its CAR-T programs, including CTX130 for solid tumors.
  • Strategic Partnerships: CRISPR Therapeutics has expanded its collaboration with Vertex Pharmaceuticals and entered into new partnerships to explore additional therapeutic areas.
  • Manufacturing Facility: The company recently opened a state-of-the-art manufacturing facility to support the production of its gene-editing therapies.

Investment Considerations

Strengths:

  • Leadership in CRISPR-Cas9 technology.
  • Strong pipeline of innovative therapies.
  • Strategic partnerships with industry leaders.
  • Robust intellectual property portfolio.

Risks:

  • High dependence on a few key products.
  • Regulatory and ethical challenges.
  • Intense competition in the biotechnology sector.

Conclusion

CRISPR Therapeutics AG is a trailblazer in the field of gene editing, with a strong pipeline of transformative therapies and strategic partnerships that position it for long-term success. While the company faces challenges such as regulatory hurdles and competition, its leadership in CRISPR-Cas9 technology and commitment to innovation make it a compelling player in the biotechnology industry. With the potential commercialization of exa-cel and advancements in CAR-T therapies, CRISPR Therapeutics is poised for significant growth in the coming years.